Regulatory intelligence and policy teams at pharmaceutical trade associations, large sponsors, and regulatory affairs consultancies use this agent when drafting public comments on FDA or EMA draft guidances during the comment period, ensuring that the sponsor's or industry body's scientific and operational concerns are articulated with regulatory precision and supported by specific evidence to maximise the likelihood of influencing the final guidance.